Olanzapine Market by Application, Route of Administration, Distribution Channel, and Geography: Forecast to 2027

Olanzapine is an oral tablet used in the treatment of depression, schizophrenia and bipolar I disorder. It is available as an orally disintegrating tablet which dissolves quickly in the mouth and a tablet. The side effects related to olanzapine are difficulty in swallowing, dizziness, headache, feeling tired or restless, and drowsiness. Olanzapine is also used along with fluoxetine for the treatment of depression in adults and children at least 10 years old who have bipolar I disorder. Expansion of the olanzapine market size is propelled by surge in the population with schizophrenia of several nations, such as China and Japan. As the global population rise, individuals do not get complete nutrition for kids, which result in increase in occurrence of schizophrenia. Apart from this, the rise in government support for healthcare infrastructure advances further fuels the olanzapine market growth. Additionally, growth in the dysfunctional behavior among people contributes toward the expansion of the market. However, the adverse affects of the drugs used by people may hamper the market growth. The Olanzapine Market is likely to grow at a rate of 2.1% CAGR by 2027.

Olanzapine Market by Application

• Bipolar Disorder
• Others
• Schizophrenia

Olanzapine Market by Route of Administration

• Oral
• Parenteral

Olanzapine Market by Distribution Channel

• Hospital Pharmacies
• Drug stores and Retail Pharmacies
• Online Providers

Olanzapine Market by Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

On the basis of application, the market for Olanzapine is classified into Bipolar Disorder, Others and Schizophrenia. The Schizophrenia segment type is anticipated to hold the greatest share in the market. The factor which propels the growth of the segment is an increase in incidences of mental illness. For example, as per the National Institute of Mental Health (NIH) in the U.S., 52.9 million adults lived with mental illness in 2020. Therefore, a rise in incidences of mental illness, which needs olanzapine medication as a treatment to treat the disease, accelerates market growth.

Further, the market is based on Route of Administration, which is furcated into Oral and Parenteral. Compared to parenteral the oral route of administration segment is having the significant share in the market. This can be ascribed to the increased adoption of oral drugs owing to high patient compliance, noninvasive, convenient to handle, and not needing any specific sterile conditions. For example, the Sun Pharmaceutical Industries Ltd. provides oral olanzapine tablets.

Based on the market for distribution channel, the market is segmented into Hospital Pharmacies, Drug stores and Retail Pharmacies and Online Providers. The Drug stores and Retail Pharmacies are projected to capture the maximum share in the market. The easy availability of olanzapine drugs in the Drug stores and Retail Pharmacies is the key reason for the segment growth.

As per the geographical analysis, the olanzapine market is segregated as North America, Europe, Asia Pacific and Rest of the World. North America has the significant share in the market. This is owing to the universal usage of the product by patients in the region and leading manufacturers creating the product in the region.

Globally, the incidence of bipolar treatment is a vital driver of the olanzapine market growth. There is no exact medication available for the olanzapine disorder. Factors such as disturbing thoughts, loss of interest in life, abnormal emotions are few of the symptoms of olanzapine. These disorders are same to depression. The more availability of bipolar treatment is fueling more demand for the global olanzapine market. Therefore, it fuels the global olanzapine market growth.

Few notable vendors of the olanzapine market are Alkermes, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, Eli Lilly and Company, apotex inc., Dr. Reddy's Laboratories Ltd., Torrent Group, Novartis AG, and Viatris.

Henceforth, the schizophrenia, bipolar and other mental disorders are considered as a serious condition across the world, regardless of age, gender and other factors. There is no proper treatment for these conditions but, the olanzapine is considered to have to have significant role in controlling the symptoms of mental disorders.

Key reasons to purchase the report:

• The several factors are included in the study which are impacting the market growth and restricting the market.
• This report consists of the segmentations and sub segmentations and the segment’s contribution to the market growth.
• The report further covers the profiles of the key vendors in market coupled with their strategies such as product launches, company expansions and acquisitions.
• Further, the report depicts the penetration of the market in the various regions.